Pro Research: Wall Street delves into Alnylam Pharmaceuticals
Explore Wall Street's expert insights with this ProResearch article, which will exclusively be available to InvestingPro subscribers soon. Enhance your investment strategy with ProPicks, our newest product featuring strategies that have outperformed the S&P 500 by up to 700%. This Cyber Monday, enjoy up to 60% off, plus an extra 10% off a 2-year subscription with the code research23 , reserved for the first 500 quick subscribers. To ensure ongoing access to valuable content like this, step up your investment game with InvestingPro.
In the biopharmaceutical landscape, Alnylam Pharmaceuticals continues to be a company of interest, with its dedication to RNA interference (RNAi) therapeutics for the treatment of serious diseases. The company's stock, traded as NASDAQ:ALNY, remains a focal point for analysts, who have provided updated insights into its prospects, performance, and potential, reflecting a positive industry view and confidence in its strategic direction.
Alnylam showcases a dynamic portfolio that includes FDA/EMA-approved drugs for rare diseases and several promising candidates in development. The company has recently disclosed initial data for ALN-TTRsc04 targeting ATTR amyloidosis, which shows promise for supporting annual dosing, and ALN-KHK for Type 2 Diabetes, indicating progress in their pipeline. Zilebesiran, aimed at treating hypertension, continues to generate buzz, particularly with the Phase II KARDIA-2 data expected in the first half of 2024, which will explore its efficacy combined with standard hypertension medication. The KARDIA-3 study, targeting higher-risk patients, is on track for mid-2024.
The HELIOS-B Phase 3 trial for AMVUTTRA in ATTR amyloidosis with cardiomyopathy is anticipated to
Read more on investing.com
